Encora Therapeutics - About the company
Encora Therapeutics is a seed company based in Cambridge (United States), founded in 2018 by Daniel Carballo and Kyle Pina. It operates as a Developer of smart devices for the treatment of neurological movement disorders. Encora Therapeutics has raised $1.5M in funding from Innospark Ventures. The company has 31 active competitors, including 11 funded and 2 that have exited. Its top competitors include companies like Cala Health, PhotoPharmics and Aleva Neuro.
Company Details
Encora Therapeutics is a developer of smart devices for the treatment of neurological movement disorders. It provides solutions for the people suffering from hand tremors, Parkinson's diseases, essential tremor, and others. It uses wearable technology, signal processing, reinforcement learning, and patient sensing to provide personalized, non-invasive remedies for patients with neurological movement disorders.
- Website
- encoratherapeutics.com
- Social
- Email ID
- *****@encoratherapeutics.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2018
Location
Cambridge, United States
Stage
Seed
Total Funding
$1.5M in 1 round
Latest Funding Round
Investors
Ranked
3rd among 31 active competitors
Employee Count
19 as on Mar 31, 2026
Similar Companies
Sign up to download Encora Therapeutics' company profile
Encora Therapeutics's funding and investors
Encora Therapeutics has raised a total funding of $1.5M over 1 round. Its latest funding round was a Seed round on Sep 30, 2020 for $*****. 3 investors participated in its latest round. Encora Therapeutics has 4 institutional investors.
Here is the list of recent funding rounds of Encora Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 30, 2020 | 1967594 | Seed | 9107168 | 2346852 | 7324410 | 7750971 |
Access funding benchmarks and valuations. Sign up today!View details of Encora Therapeutics's funding rounds and investors
Encora Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Encora Therapeutics are Daniel Carballo and Kyle Pina. Daniel Carballo is the CEO of Encora Therapeutics.
Here are the details of Encora Therapeutics' key team members:
- Daniel Carballo: Co-Founder & CEO of Encora Therapeutics. Contact Info: 1 email address
- Kyle Pina: Co-Founder, VP of Engineering of Encora Therapeutics.
View details of Encora Therapeutics's Founder profiles and Board Members
Encora Therapeutics' employee count trend
Encora Therapeutics has 19 employees as of Mar 26. Here is Encora Therapeutics's employee count trend over the years:
Uncover Encora Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Encora Therapeutics's Competitors and alternates
Top competitors of Encora Therapeutics include Cala Health, PhotoPharmics and Aleva Neuro. Here is the list of Top 10 competitors of Encora Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Cala Health 2013, Stanford (United States), Series D | Developer of a wearable non-invasive neuromodulation device | $257M | 64/100 | |
2nd |  PhotoPharmics 2011, American Fork (United States), Series B | Developer of non-invasive phototherapy for Parkinson's disease | $45.7M | 56/100 | |
3rd |  Encora Therapeutics 2018, Cambridge (United States), Seed | Developer of smart devices for the treatment of neurological movement disorders | $1.5M | 53/100 | |
4th |  Aleva Neuro 2008, Lausanne (Switzerland), Series E | Develops implantable deep brain stimulation systems that enables therapies for neurological diseases | $57M | 46/100 | |
5th |  InBrain Pharma 2018, Paris (France), Seed | Developer of therapeutic solutions for the treatment of neurodegenerative diseases | $3.15M | 46/100 | |
6th |  Civitas Therapeutics 2009, Chelsea (United States), Acquired | Pulmonary delivery therapies for relief from intermittent debilitating motor fluctuations | $128M | 45/100 | |
7th | Charco Neurotech 2019, Cambridge (United Kingdom), Seed | Developer of non-invasive wearable device for people with Parkinson's | $17.7M | 45/100 | |
8th | Sapiens Neuro 2011, Munich (Germany), Acquired | Developer of brain stimulation device to treat neurodegenerative disorders | $55.9M | 42/100 | |
9th | NDI Medical 2002, Cleveland (United States), Series A | Neurodevice venture capital firm developing innovative technologies for neurological function restoration | $2.11M | 42/100 | |
10th | Provider of smart devices for managing Parkinson's disease | - | 40/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Encora Therapeutics's competitors? Click here to see the top ones
Encora Therapeutics's Investments and acquisitions
Encora Therapeutics has made no investments or acquisitions yet.
News related to Encora Therapeutics
Media has covered Encora Therapeutics for a total of 2 events in the last 1 year, 1 of them has been about people movement.
•
•
Encora Therapeutics Names Nadim Yared as Chairman and Chief Executive OfficerBusiness Wire•Oct 03, 2025•Encora Therapeutics
•
•
Zeta Surgical raises $5.2M for robotic surgery platformMassDevice•Mar 10, 2022•Zeta, Innospark, TSVC, Y Combinator and 4 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Encora Therapeutics
Explore our recently published companies
- Cengage Learning - Boston based, 2007 founded, Funding Raised company
- Hoyasan Labs - Bengaluru based, 2021 founded, Funding Raised company
- Nomad - Toronto based, 2025 founded, Seed company
- Jamesleatherco - Unfunded company
- Geospatial Collaborative - Tucson based, 2017 founded, Unfunded company
- samra - Unfunded company
